Clinical Trials
14 trialsNCT06352502 2024-04-08
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Tang-Du Hospital
Unknown
NCT06339242 2024-04-01
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital
Phase 2 Unknown
NCT04401059 2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4 Unknown
NCT05987826 2023-08-14
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage â…¡-â…¢B EGFR Sensitive Mutant NSCLC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05813522 2023-04-14
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT04895930 2023-01-06
FOCUS-A
Shanghai Chest Hospital
Phase 2 Unknown
NCT05548348 2022-09-21
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT05255406 2022-08-04
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
Fudan University
Phase 2 Unknown
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT05165355 2022-01-18
ATHEM
Tongji University
Phase 2 Unknown
NCT05079022 2021-10-15
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Peking University People's Hospital
Phase 1/2 Unknown
NCT04982900 2021-10-05
TERMGGO
Ruijin Hospital
Phase 2 Unknown
NCT04970693 2021-07-21
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
Sun Yat-sen University
Phase 2 Unknown
NCT04965831 2021-07-16
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown